JAK1 and neoplasm: Other factors implicated in the lack of response or resistance to immunotherapy include absence of tumor infiltrating lymphocytes (TILs), lack of tumor antigenicity, dysregulation of WNT-β-catenin pathway13,14, PTEN loss15, p53 loss16 and deletional mutations in the JAK1/2–STAT17 signaling pathway.